Replimune Group, Inc. (REPL)
| Market Cap | 1.43B +245.9% |
| Revenue (ttm) | n/a |
| Net Income | -313.94M |
| EPS | -3.38 |
| Shares Out | 93.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,272,476 |
| Open | 13.62 |
| Previous Close | 13.65 |
| Day's Range | 13.62 - 15.68 |
| 52-Week Range | 1.50 - 15.68 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 19.33 (+26.84%) |
| Earnings Date | Aug 18, 2026 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for REPL stock is "Buy." The 12-month stock price target is $19.33, which is an increase of 26.84% from the latest price.
News
Replimune Announces Pricing of $150 Million Underwritten Offering
BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, to...
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.
Replimune price target raised to $20 from $16 at BMO Capital
BMO Capital raised the firm’s price target on Replimune (REPL) to $20 from $16 and keeps an Outperform rating on the shares. Replimune received a key regulatory win with Tudriqev…
Wedbush upgrades Replimune to Outperform following FDA decision
As previously reported, Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up from $12. The firm notes the Food and Drug Administration granted accelerated…
Replimune upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up from $12.
Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma
Replimune (REPL) announced that the FDA has granted accelerated approval for Tudriqev, previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanc...
Replimune Group Press release: FDA announcement
Replimune Group issued a press release on August 6, 2026, disclosing material business information to investors.
Replimune Group Slides: FDA announcement
Replimune Group has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
US FDA approves Replimune's skin cancer drug
The U.S. Food and Drug Administration has approved Replimune's drug for a difficult-to-treat form of skin cancer, the company said on Thursday, giving the biotech firm its first marketed product af...
FDA Approves Replimune's Melanoma Drug On Third Attempt
The agency had turned down two earlier applications over clinical data-quality concerns.
Replimune upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Replimune (REPL) to Outperform from Market Perform with a price target of $17, up from $11. The firm has “high conviction” the FDA will grant RP-1 plus nivolumab…
Why Is Replimune (REPL) Stock Up Today?
Replimune stock rallied on Friday thanks to an FDA update that acted as a catalyst for analyst upgrades.
Piper upgrades Replimune to Overweight on better odds of RP1 approval
As previously reported, Piper Sandler analyst Allison Bratzel upgraded Replimune (REPL) to Overweight from Neutral with a price target of $14, up from $9. The postive FDA panel vote supporting…
Replimune upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Replimune (REPL) to Overweight from Neutral with a $14 price target
This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment
Replimune stock soars after a FDA advisory committee votes that the company's study on its skin cancer treatment is ‘clinically meaningful.'
Replimune price target raised to $12 from $9 at Wedbush
Wedbush raised the firm’s price target on Replimune (REPL) to $12 from $9 and keeps a Neutral rating on the shares. The firm notes the FDA convened an Advisory Committee…
Why is Biotech Stock Replimune (REPL) Soaring Over 120% Today?
Shares in biotechnology company Replimune ($REPL) soared over 120% in pre-market trading today after U.S. regulators gave the thumbs up to its skin-cancer fighting drug. FDA Votes in Favor The…
Replimune surges after FDA advisers back skin cancer drug
Shares of Replimune more than doubled premarket on Friday after the U.S. Food and Drug Administration's panel of outside advisers voted to back trial results for its drug for a type of skin cancer.
Replimune upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Replimune (REPL) to Overweight from Neutral without a price target citing the FDA panel vote supporting RP1 approval for advanced melanoma after anti-PD-1 failure. The “over...
Replimune confirms FDA AdCom voted in favor of experimental melanoma treatment
The company states: “Replimune (REPL) announced the outcome of today’s meeting of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee, or CTGTAC, whic...
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
FDA panel votes 10-3 in favor of Replimune’s experimental melanoma treatment
17:42 EDT FDA panel votes 10-3 in favor of Replimune’s (REPL) experimental melanoma treatment
A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works
Independent experts voted 10-3 despite regulators' concern about the design of the company's pivotal cancer trial.
US FDA panel backs Replimune skin cancer drug study data
A panel of outside advisers to the US Food and Drug Administration voted to back results from a trial studying Replimune's drug for a type of skin cancer in a meeting on Thursday.
Replimune Group Slides: Investor presentation
Replimune Group has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.